Germany Mosquito-Borne Infections Molecular Testing Market Insight
The Germany Mosquito-Borne Infections Molecular Testing Market size is growing at a 6.5% CAGR, driven by rising climate-related mosquito expansion, travel-associated infections, and rapid adoption of PCR-based multiplex molecular diagnostics.
Germany Mosquito-Borne Infections Molecular Testing Market Insights and Forecasts to 2035
- The Germany Mosquito-Borne Infections Molecular Testing Market Size Was Estimated at USD156.4Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.5% from 2025 to 2035
- The Germany Mosquito-Borne Infections Molecular Testing Market Size is Expected to Reach USD 293.5Million by 2035
Notable Insights for the Germany Mosquito-Borne Infections Molecular Testing Market
- By test type, the PCR- based molecular diagnostics dominate the market, accounting for approximately 55-58% share in 2025. The system achieves detection of early infections through its high sensitivity which enables simultaneous identification of dengue and Zika and chikungunya viruses.
- By end-user, the hospitalsdominate the market, accounting for approximately60-65% share in 2025. Germany maintains its lead position because of its extensive hospital system which operates as a centralized network for conducting infectious disease testing and monitoring disease outbreaks
- Germany recorded approximately over 1,000–1,200 dengue fever cases annually in recent years (post-2022 average range) which resulted in higher demand for molecular diagnostic testing including RT-PCR.
Download the eBook (ToC)
- More than 70% of large diagnostic laboratories in Germany use PCR-based molecular testing platforms for infectious disease detection which includes viral pathogens that cause dengue Zika and West Nile virus.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Germany mosquito-borne infections molecular testing market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Mosquito-Borne Infections Molecular Testing Market
- QIAGEN N.V. (Germany HQ operations)
- Roche Diagnostics Germany
- Siemens Healthineers
- BioNTech Diagnostics Division
- Altona Diagnostics
- Bosch Healthcare Solutions
- TIB Molbiol (Roche subsidiary)
- Bruker Corporation (Germany operations)
- Hologic Germany
- Becton Dickinson (BD Germany diagnostics
Recent Developments:
- In October 2025, Roche expanded its dengue and arbovirus PCR testing menu which received CE-marking for cobas systems in Germany to provide clinical laboratories with faster multiple testing capabilities for mosquito-transmitted diseases.
Market Segmentation:
Germany Mosquito-Borne Infections Molecular Testing Market, By Test Type
• RT-PCR Assays (dominant)
• Isothermal Amplification Tests
• Multiplex PCR Panels
• Next-Generation Sequencing (NGS)
Germany Mosquito-Borne Infections Molecular Testing Market, By Disease Type
• Dengue Virus (dominant)
• Zika Virus
• Chikungunya
• West Nile Virus
• Malaria (imported cases)
Germany Mosquito-Borne Infections Molecular Testing Market, By End User
• Hospitals
• Diagnostic Laboratories (dominant)
• Public Health Institutes
• Academic & Research Centers)
Expert Views:
Germany's market for testing mosquito-borne infections now uses molecular testing methods to conduct climate-based disease surveillance instead of travel-related testing. The molecular diagnostic testing market is growing because of three factors which include the development of RT-PCR multiplex platforms, the increase in local dengue transmission cases, and the establishment of new infectious disease monitoring systems by the European Union.